Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZM 3329

X
Drug Profile

ZM 3329

Alternative Names: ZM-3329

Latest Information Update: 11 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Simcere Zaiming
  • Class Antineoplastics
  • Mechanism of Action H2AFX protein stimulants; Proto-oncogene protein p21(ras) expression stimulants; Werner syndrome helicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Endometrial cancer; Gastrointestinal cancer

Most Recent Events

  • 05 Apr 2024 Preclinical trials in Endometrial cancer in China (PO), prior to April 2024
  • 05 Apr 2024 Preclinical trials in Gastrointestinal cancer in China (PO), prior to April 2024
  • 05 Apr 2024 Pharmacodynamics, Pharmacokinetics and adverse events data from preclinical trials in endometrial cancer and gastrointestinal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top